Lannett Company, Inc.
$0.69$0.00 (0.0%)
Lannett Company, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.57% below the high.
NASDAQ · ADMP · USD
Stock price, earnings
Quote as of Sep 7, 2023, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Adamis Pharmaceuticals Corporation’s quoted price sits in the lower half of its reported 52-week range, 96.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Adamis Pharmaceuticals Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company primarily engaged in the development and commercialization of products within the United States, targeting key therapeutic domains such as allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its current product portfolio includes SYMJEPI pre-filled epinephrine syringes for the emergency treatment of severe allergic reactions, including anaphylaxis; dry powder inhaler products designed for asthma management; and injectable naloxone for addressing opioid overdose. Additionally, Adamis is advancing pipeline candidates such as APC400, a tempol gel aimed at mitigating radiation-induced dermatitis in cancer patients, and APC410, formulated to treat a range of respiratory ailments including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19. The company also extends its offerings to include corticosteroids, hormone replacement therapies, hospital outsourcing products, and other injectables, alongside a line of veterinary pharmaceutical products. Established in 2006, Adamis Pharmaceuticals Corporation maintains its headquarters in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2021 | Mar 31, 2022 | -$0.06-50.0% vs estimate | -$1.16M-130.84% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.69$0.00 (0.0%)
Lannett Company, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.57% below the high.
CA$0.02CA$0.00 (0.0%)
Red White & Bloom Brands Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.02+$0.00 (+4.79%)
VIVO Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.5% below the high.
A$0.02-A$0.00 (-4.76%)
Epsilon Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.12+$0.00 (+2.52%)
Acreage Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$0.01-$0.00 (-1.95%)
Delta 9 Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.33% below the high.
$0.51-$0.16 (-23.29%)
Lucy Scientific Discovery Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.99% below the high.